Methods of L-Dopa Extraction by the Method of Analytical Determination for Parkinson’s Neurodegenerative Disease
Main Article Content
Abstract
Levodopa the majority of Parkinson's disease patients eventually require levodopa medication. The chemical dopamine, which is produced when levodopa is absorbed by brain nerve cells, is used for send messages from brain regions,neurons,and synaptic memberane. that regulate movement.this neurodegenerative disease can cause uncontrollable movements, shivering, and problem balancing and muscle control. Only a few plants in the Fabaceae family have substantial amounts of isolated L-dopa; the rest are either chemically synthesized or derived from natural sources.(HPLC) added with mass spectrometry else it can added with UV-visible detection. Most frequently, HPLC is utilized.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Balestrino, R.; Schapira, A.H.V. Parkinson disease. Eur. J. Neurol.2020, 27, 27–42. [Google Scholar] [CrossRef] [PubMed]
II. Khan, S.T.; Ahmed, S.; Gul, S.; Khan, A.; Al-Harrasi, A. Search for safer and potent natural inhibitors of Parkinson’s disease. Neurochem. Int.2021, 149, 105135. [Google Scholar] [CrossRef] [PubMed]
III. Hall, M.F.E.; Church, F.C. Integrative Medicine and Health Therapy for Parkinson Disease. Top. Geriatr. Rehabil.2020, 36, 176–186. [Google Scholar] [CrossRef]
IV. Rezak, M. Current Pharmacotherapeutic Treatment Options in Parkinson’s Disease. Disease-A-Month2007, 53, 214–222. [Google Scholar] [CrossRef]
V. Nutt, J.G. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord.2008, 23, 580–584. [Google Scholar] [CrossRef]
VI. Tizabi, Y.; Getachew, B.; Aschner, M. Novel Pharmacotherapies in Parkinson’s Disease. Neurotox. Res.2021, 39, 1381–1390. [Google Scholar] [CrossRef]
VII. Poewe, W.; Antonini, A. Novel formulations and modes of delivery of levodopa. Mov. Disord.2015, 30, 114–120. [Google Scholar] [CrossRef]
VIII. Müller, T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs2015, 75, 157–174. [Google Scholar] [CrossRef]
IX. Valdés, R.H.; Puzer, L.; Gomes, M.; Marques, C.E.S.J.; Aranda, D.A.G.; Bastos, M.L.; Gemal, A.L.; Antunes, O.A.C. Production of L-DOPA under heterogeneous asymmetric catalysis. Catal. Commun.2004, 5, 631–634. [Google Scholar] [CrossRef]
X. Patil, S.A.; Apine, O.A.; Surwase, S.N.; Jadhav, J.P. Biological sources of L-DOPA: An alternative approach. Adv. Park. Dis.2013, 2, 81–87. [Google Scholar] [CrossRef]
XI. Lampariello, L.; Cortelazzo, A.; Guerranti, R.; Sticozzi, C.; Valacchi, G. The magic velvet bean of mucunapruriens. J. Tradit. Complement. Med.2012, 2, 331–339. [Google Scholar] [CrossRef]
XII. Onofrj M, Bonanni L, Thomas A: An expert opinion on safinamide in Parkinson's disease. Expert OpinInvestig Drugs. 2008 Jul;17(7):1115-25. doi: 10.1517/13543784.17.7.1115 . [Article]
XIII. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. ClinPharmacokinet. 2002;41(4):261-309. [Article]
XIV. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s11. [Article]
XV. Corvol JC, Mariani LL. [Therapeutic and pharmacologic perspectives in Parkinson's disease]. Rev Prat. 2018 May;68(5):515-519. [PubMed]
XVI. Ebada MA, Alkanj S, Ebada M, Abdelkarim AH, Diab A, Aziz MAE, Soliman AM, Fayed N, Bahbah EI, Negida A. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review. CNS NeurolDisord Drug Targets. 2019;18(4):317-325. [PubMed]
XVII. Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-Induced Neuropathy: A Systematic Review. MovDisordClinPract. 2019 Feb;6(2):96-103. [PMC free article] [PubMed]
XVIII. Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, Lamm CI, Tracy SL, Rosenberg RS., American Academy of Sleep Medicine. The treatment of restless legs